All In Biotech

Drug Trial Radar · NCT00968812

CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy

Last checked: Nov 20, 2026Latest source record: Jan 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,452 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,452

Actual

Start

Sep 2009

Primary completion

Dec 2011

Study completion Jan 2013

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 31, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the efficacy, safety, and tolerability of canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • GlimepirideDrug

    Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.

  • Canagliflozin (JNJ-28431754)Drug

    Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.

  • MetforminDrug

    Metformin will be given orally at the protocol-specified dose for 104 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c From Baseline to Week 52Time frame: Day 1 (Baseline) and Week 52

Locations

138 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    Calera, Alabama

  • Site not named

    Gilbert, Arizona

  • Site not named

    Mesa, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Buena Park, California

  • Site not named

    Encinitas, California

  • Site not named

    Fresno, California

  • Site not named

    Lincoln, California

  • Site not named

    Roseville, California

  • Site not named

    San Diego, California

  • Site not named

    Westlake Village, California

  • Site not named

    Chipley, Florida

  • Site not named

    Marianna, Florida

  • Site not named

    Oldsmar, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    Perry, Georgia

  • Site not named

    Nampa, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Vernon Hills, Illinois

  • Site not named

    Valparaiso, Indiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Elkridge, Maryland

  • Site not named

    Bloomfield Hills, Michigan

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Canal Fulton, Ohio

  • Site not named

    Gallipolis, Ohio

  • Site not named

    Mason, Ohio

  • Site not named

    Perrysburg, Ohio

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Yukon, Oklahoma

  • Site not named

    Fleetwood, Pennsylvania

  • Site not named

    Greenville, South Carolina

  • Site not named

    Nashville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Odessa, Texas

  • Site not named

    Pearland, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Danville, Virginia

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.